Introduction
Retinoblastoma is the most common intra-ocular malignancy arising from the developing retina in children and occurs in approximately one of every 15 000-20 000 births, which seriously threaten the vision and lives of children (Yun et al. 2011) . Thanks to major advances in the molecular biology of the tumour and the development of targeted therapy, the 5-year overall survival rate of children with retinoblastoma is 87% to 99% in developed countries. However, the mortality rate still exceeds 39% in developing countries due to the limitation of health care.
Many therapeutic modalities have been developed, including systemic chemotherapy, focal or consolidation therapy, external beam radiotherapy (EBRT). Yet, enucleation, the complete removal of the eyeball, remains an important option though it is the oldest surgical procedure in ophthalmology (Shields et al. 2006 (Shields et al. , 2009 . Following the report in 2008 of the treatment of children with retinoblastoma by selective ophthalmic artery chemotherapy (OAC), intra-arterial chemotherapy (IAC) has become the first-line treatment for advanced and recurrent intra-ocular retinoblastoma for it could significantly reduce the enucleation and minimize the toxicity of systemic chemotherapy (Abramson et al. 2008) . Therefore, more and more specialized centres have used IAC for retinoblastoma and reported its outcome and complications (Shields et al. 2014) . In China, approximately 1100-1500 new cases of retinoblastoma are diagnosed every year. Most eyes of Chinese patients with retinoblastoma are always at a relative advanced stage without timely diagnosis and appropriate treatment. Since we realized that IAC is effective and has acceptable ocular complications and minimal systemic toxicity, we mainly use IAC for the treatment of advanced intraocular retinoblastoma at our centre. Although many specialized centres have reported that IAC is a safe and effective treatment option for patients with retinoblastoma, there are few studies to investigate the factors influencing the outcome of IAC for retinoblastoma (Peterson et al. 2011; Schaiquevich et al. 2013; Tuncer et al. 2016) .
In this study, we retrospectively reviewed the outcome of IAC for retinoblastoma and determined the factors influencing clinical outcomes using univariate and multivariate analyses.
Materials and Methods
The study subjects included patients with unilateral or bilateral intra-ocular retinoblastoma undergoing IAC at our centre from January 2011 to April 2013. Before IAC, patients had received no prior treatment to the eye, or previously treated with laser, cryotherapy, brachytherapy, systemic chemotherapy or periocular chemotherapy. Patients were excluded if the retinoblastoma could be controlled with focal treatments (laser, cryotherapy or brachytherapy) or was at very advanced stage (neovasular glaucoma or suspected invasion of postlaminar optic nerve, sclera, or anterior chamber) or if they have extraocular invasion, documented metastatic disease or structural brain abnormalities. This retrospective study was approved by the ethics committee of Guangzhou Women and Children's Medical Center. The treatment procedure, possible complications, expected outcomes and the associated risks were explained in detail before the treatment. Written informed consent was obtained from the carers or guardians on the behalf of all the children enrolled in this study.
The patients were divided into two groups according to previous treatment: (1) failure of previous treatment: patients failed to respond adequately to previous treatment including systemic chemotherapy, periocular chemotherapy, and relapsed; (2) sequential IAC treatment: patients previously treated with laser, cryotherapy, brachytherapy, systemic chemotherapy or periocular chemotherapy which had a certain effect, but they wanted to choose IAC instead of previous treatment.
Classification is necessary to determine appropriate management and predict outcome. In this study, the eyes were classified according to the International Intraocular Retinoblastoma Classification (IIRC), which was developed by Murphree (2005) .
All IAC procedures were performed by the interventional radiologists under general anaesthesia. The femoral artery was punctured with a 4-French (4-F) arterial sheath using Seldinger technique, and then heparin (75 IU/kg) was administered by intravenous injection to avoid thrombosis. Under X-ray guidance, the ipsilateral internal carotid artery is catheterized with a 4-F Cobra guide catheter (Terumo, Tokyo, Japan). Serial arteriograms helped to visualize the ocular and cerebral vasculature and to obtain the path of the ophthalmic artery from the internal carotid artery. Using fluoroscopy and road mapping, the ophthalmic artery was catheterized with a 1.7-F microcatheter(ev3Neurovascular,Inc.,Irvine, CA, USA). When the microcatheter was placed at the ostium of the ophthalmic artery, an angiogram of the ophthalmic artery was taken (Fig. 1) . The chemotherapeutic agents used in the protocol included melphalan and topotecan. The dose of melphalan was not more than 0.5 mg/kg, and topotecan dose was 1 mg. Melphalan or topotecan was diluted with 0.9% saline to obtain a volume of 30 cm 3 of solution, which was administered in a pulsatile fashion over 30 min to avoid streaming and inhomogeneous drug delivery. For patients with bilateral retinoblastoma, after drugs were infused into one of the eyes, the catheter was retracted to the aorta and then guided into the ophthalmic artery of the other eye using the same procedure. At the conclusion of the infusion, the microcatheter was withdrawn and the sheath was removed. Haemostasis of the femoral artery was then achieved by manual compression for 10-15 min. Patients were monitored overnight before discharge. Whenever the ophthalmic artery was not appropriate for selective catheterization, the middle meningeal artery technique was used as an alternative. The technical success rate of IAC (i.e. successful injection of chemotherapy into the ophthalmic artery) was recorded. Each session of IAC for each patient was performed at a 4-week interval, and the necessity for further sessions was decided based on tumour response. After two cycles of IAC, it indicated treatment failure if the size of tumours increased or tumour vascularity was still observed.
At each 4-week follow-up, detailed ophthalmic examination was performed by the ocular oncologist. The ophthalmic evaluation included an external examination and a pupil and Using fluoroscopy and roadmap guidance, the 1.7-F microcatheter was selectively catheterized into the ophthalmic artery. (C) When the microcatheter was in a stable position at the ostium of the ophthalmic artery, chemotherapy drugs were pulse-injected. motility evaluation. The systemic evaluation included an interval history and routine blood test. The follow-up data for each patient, including ocular adverse events, systemic adverse events, globe salvage and the greatest basal dimension of the tumour, was collected.
Data were expressed as mean AE SD and analysed using SPSS 16.0 statistical software package (SPSS Inc., Chicago, IL, USA). Univariate and multivariate analyses were performed to determine the factors associated with clinical outcome. p Value of <0.05 indicated statistical significance.
Results
This study retrospectively reviewed 107 eyes of 73 patients with retinoblastoma undergoing IAC. The mean follow-up period was 13.6 months (range, 3-28 months) after initial IAC and 9.1 months (range, 1-26 months) after the ultimate failure of IAC. Thirty-one patients (42.4%) were female and 42 (57.6%) were male. The median age of patients at first IAC was 20 months (range, 4-95 months). Thirty-five patients (32.7%) displayed unilateral and 72 (67.3%) displayed bilateral disease. According to IIRC, 107 eyes were classified as Group E (n = 29, 27.1%), Group D (n = 56, 52.3%), Group C (n = 11, 10.3%), and Group B (n = 11, 10.3%). IAC was performed as primary therapy in 30 eyes (28.1%) and secondary therapy in 77 eyes (71.9%). Of 77 eyes treated with IAC as secondary therapy, 62 eyes (57.9%) failed to respond adequately to previous treatment (mainly systemic chemotherapy) and 15 eyes (14%) previously underwent laser (12 eyes, 11.2%), systemic chemotherapy (2 eyes, 1.9%) and periocular chemotherapy (1 eye, 0.9%) with a certain effect. Characteristics of patients and eyes are shown in Table 1 .
Treatment features are shown in Table 2 . IAC was performed in 107 eyes of 73 patients, with a median of 3.1 sessions per eye (range, 2-5 sessions). Of 343 catheterizations for 107 eyes, 338 procedures were successful with a technical success rate of 98.5%. Five procedures were stopped because of internal carotid artery spasms. Forty eyes (37.4%) were infused with single agent melphalan and 67 eyes (62.6%) with melphalan plus topotecan.
Of 107 eyes, initial response was found in all eyes, but long-term control with globe salvage was maintained in 84 eyes. An overall globe salvage rate of 78.5% was observed during followup periods according to calcification or inactivation of tumours. Globe salvage was achieved in Group B (n = 11/11, 100%), Group C (n = 11/11, 100%), Group D (n = 44/56, 78.6%) and Group E (n = 18/29, 62%; Fig. 2A ). In primary-treated patients, the success Table 3 ). The enucleation rate in patients who failed to previous treatment, or with advanced retinoblastoma (Group D and Group E), or treated with melphalan alone was significantly higher than in those who received no previous treatment, or with early retinoblastoma, or treated with melphalan plus topotecan, respectively. The globe salvage rate was not associated with sex, laterality or IAC catheterization technique (p > 0.05, respectively). Multivariate analysis demonstrated that tumour staging (p = 0.04) and previous treatment (p < 0.001) were independently related to globe salvage.
The treatment complications are listed in Table 4 . Ocular adverse events included eyelid oedema (n = 15, 14%), conjunctival congestion (n = 32, 29.9%) and excessive tearing (n = 10, 9.3%), which could recover itself. Long-term complications included vitreous haemorrhage (n = 9, 8.4%), subretinal haemorrhage (n = 10, 9.3%), retinal vasculopathy (n = 8, 7.5%) and ophthalmic artery spasm with reperfusion (n = 5, 4.7%). There were no patients with systemic adverse events, such as stroke or sepsis. Sixteen patients experienced a fever (not exceeding 38.5°C) following treatment. Transient vomiting occurred in 20 patients. Grade I transient myelosuppression (according to the Common Terminology Criteria for Adverse Events, decreased number of white blood cells, red blood cells or thrombocytes) was noted in ten patients. Multivariate analysis indicated that age, weight, the number of previous systemic chemotherapy and length of latency between systemic chemotherapy and IAC were not risk factors for systemic toxicity (p > 0.05). There were no secondary neoplasms and technical complications observed. There was no damage to liver or renal function because of IAC.
Discussion
With the development of modern medicine, the current trend in the management of retinoblastoma is not only to save lives but also to improve ocular salvage and preserve vision (Gobin et al. 2011) . In order to improving globe salvage rate, many therapeutic modalities have been attempted, including systemic chemotherapy, subconjunctival injection of carboplatin, intravitreal injection of melphalan and IAC (Chantada & Schaiquevich 2015) . In recent years, IAC has become an essential technique in the treatment of advanced intra-ocular retinoblastoma in children with favourable outcomes and fewer adverse effects. In this single-institution retrospective study, we investigated the outcome of IAC for retinoblastoma and determined the factors affecting its clinical outcome. The retrospective analysis of 73 patients demonstrated that IAC is an effective and safe treatment for retinoblastoma, with a technical success rate of 98.5% and an overall ocular preservation rate of 78.5%. Although some patients experienced minor sideeffects, major complications did not occur. Univariate and multivariate analyses showed that tumour staging and previous treatment were independent factors related to globe salvage. The technical success rate of IAC in this retrospective study was similar to the rates in previous reports (98%-100%; Schaiquevich et al. 2013) . Five procedures were stopped because of vascular spasms. These five patients received more than five cycles of systemic chemotherapy before IAC and more than two cycles of IAC before vascular spasms occurred. Reperfusion may be one of the high risk factors of ophthalmic artery spasm. After the first failed attempt, these five patients underwent successful catheterization without increased complications 1 or 2 weeks later.
Intra-arterial chemotherapy (IAC) was initially developed as first-line therapy for the treatment of patients with unilateral advanced retinoblastoma, and it is used as second-line therapy for relapsed retinoblastoma (Yamane et al. 2004; Shields et al. 2013) . In Shields's retrospective study, globe salvage was achieved in 72% of primary-treated patients and in 62% of secondary-treated patients (Shields et al. 2014) . In this retrospective study, globe salvage is higher when IAC is used as primary therapy (93.3%) than when it is used as secondary therapy (79%), which is consistent with previous reports (Gobin et al. 2011; Zanaty et al. 2014) . In this study, globe salvage was lower in patients who previously treated with intra venous chemotherapy, especially previous failed treatment. Most retinoblastoma showed an initial response to intravenous chemotherapy but eventually progressed. Previous studies showed that retinoblastoma cells in patients that failed to systemic chemotherapy expressed multidrug resistance protein P-glycoprotein (P-gp; Gallie et al. 1996; Chan et al. 1997; Krishnakumar et al. 2004 ). Because IAC is a technique of delivering chemotherapy directly to the eye with improving effectiveness and minimizing systemic exposure, previous treatment with intravenous chemotherapy may be the main cause of multidrug resistance.
The detailed anatomical systematic studies revealed that the orbital vascular pattern is very complex with tremendous interindividual variations, emphasizing that no two orbits are the same even though they are from the two sides of the same cadaver (Hayreh & Dass 1962; Hayreh 2006 ). Therefore, a microcatheter in the ophthalmic artery may deliver different proportions of drug even if it seems that the microcatheter is in the 'same place'. For example, the greatest flow from the ophthalmic artery was not to the eye in most patients but to the supratrochlear, dorsonasal, and mediopalpebral artery complex. The study showed that the orbital angiography performed greatly influences the success of chemosurgery (Marr et al. 2012) . However, in our study, we analysed the association of two major orbital arteries (ophthalmic artery and middle meningeal artery) with the outcome of IAC. Univariate and multivariate analyses indicated that the orbital angiography performed was not significantly related to poor clinical outcome, suggesting the delivery of drug to the target tumour in the eye via ophthalmic artery or middle meningeal artery does not affect the outcome of IAC.
In conclusion, our retrospective analysis of 107 eyes with retinoblastoma found that IAC had an overall ocular preservation rate of 78.5%. Although IAC is safe and effective, patients with previous failed treatment or advanced retinoblastoma should be carefully monitored during IAC for the necessity of further sessions of IAC or additional enucleation. * Some patients had more than one complication. * The rate of eye preservation was higher than the overall ocular preservation rate because of one eye of preservation counted for bilateral retinoblastoma patients.
